What does the quizartinib label say about indications?
Quizartinib is approved for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.
What does the quizartinib label say about dosing and how it’s taken?
The label provides dosing instructions for quizartinib, including daily oral dosing and guidance on how to take it consistently (with respect to meals/timing as specified by the product label). It also includes dose modification rules for adverse reactions and treatment interruptions (for example, for QT prolongation risk and other toxicities).
What side effects are listed on the quizartinib label?
The label lists risks and adverse reactions associated with quizartinib. A key safety area covered is cardiac effects, including QT prolongation, along with other common AML-treatment side effects such as cytopenias and gastrointestinal symptoms (as described in the prescribing information).
What monitoring does the quizartinib label require?
The quizartinib label includes monitoring recommendations, particularly for cardiac risk (ECG/QT interval) and for safety labs related to AML treatment. The label also outlines actions to take if QT prolongation or other serious adverse reactions occur.
What warnings and precautions are included on the quizartinib label?
The label includes boxed/major warnings if applicable and detailed precautions, with a focus on:
- QT prolongation and related cardiac risk
- Hematologic complications typical of AML therapy
- Other clinically important adverse reactions, with dose modification and interruption guidance
How should clinicians manage QT prolongation risk per the label?
The label describes steps such as:
- assessing baseline cardiac status (ECG/QT interval),
- avoiding or managing interacting factors that raise QT risk,
- modifying or holding quizartinib if QT increases beyond specified thresholds,
- resuming at a reduced dose if the patient stabilizes.
Does the label include drug interactions?
The label includes interaction guidance, including medicines that can increase quizartinib exposure or increase QT prolongation risk, and it provides recommendations for avoiding certain combinations or using alternative therapies when necessary.
What pregnancy/breastfeeding and fertility cautions are on the quizartinib label?
The label includes standard prescribing information for pregnancy prevention (contraception), fetal risk statements, and breastfeeding guidance, plus notes about fertility potential if included in the official labeling language.
What does the quizartinib label say about missed doses and stopping treatment?
The label includes instructions for what to do if a dose is missed, and it also provides criteria for treatment interruption, discontinuation, or continuation based on response and toxicity management.
What data support the quizartinib label?
The label is based on clinical evidence from trials in relapsed or refractory FLT3-mutated AML, with efficacy described using response rates and duration of response measures, and safety summarized from trial populations.
---
Sources
I don’t have the official quizartinib prescribing information text in the material available to me here, so I can’t accurately quote or fully reproduce the exact label wording, dosing numbers, QT thresholds, or the precise list of boxed warnings and frequencies.
If you paste the quizartinib label (or tell me the country/agency version, e.g., FDA US label, EMA EPAR, or a specific package insert PDF) I can extract the exact label sections (indications, dosing, contraindications, warnings/precautions, adverse reactions, drug interactions, and monitoring) and present them in a clean, study-ready format.